Hims & Hers Health: Partnership With Novo Nordisk Causes Sensation
Reading Time: 3 minutes
Hims & Hers surprises with strategic alliance instead of litigation: Novo Nordisk opts against a lawsuit and will collaborate closely with the telemedicine provider to make Wegovy more widely available. Short sellers come under pressure: Following the unexpected partnership, Hims & Hers' stock skyrockets by 30% – the high short interest of over 30 percent further amplifies the upward movement. Hims & Hers Health (NYSE: HIMS) is currently making headlines. Today, the company announced a strategic partnership with Novo Nordisk...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
